BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 11768620)

  • 21. Vaccine therapy for small cell lung cancer.
    Krug LM
    Semin Oncol; 2004 Feb; 31(1 Suppl 1):112-6. PubMed ID: 14981589
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1.
    Musselli C; Ragupathi G; Gilewski T; Panageas KS; Spinat Y; Livingston PO
    Int J Cancer; 2002 Feb; 97(5):660-7. PubMed ID: 11807794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.
    Sabbatini PJ; Ragupathi G; Hood C; Aghajanian CA; Juretzka M; Iasonos A; Hensley ML; Spassova MK; Ouerfelli O; Spriggs DR; Tew WP; Konner J; Clausen H; Abu Rustum N; Dansihefsky SJ; Livingston PO
    Clin Cancer Res; 2007 Jul; 13(14):4170-7. PubMed ID: 17634545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21.
    Helling F; Zhang S; Shang A; Adluri S; Calves M; Koganty R; Longenecker BM; Yao TJ; Oettgen HF; Livingston PO
    Cancer Res; 1995 Jul; 55(13):2783-8. PubMed ID: 7796403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas.
    Betting DJ; Kafi K; Abdollahi-Fard A; Hurvitz SA; Timmerman JM
    J Immunol; 2008 Sep; 181(6):4131-40. PubMed ID: 18768870
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer.
    Miles D; Papazisis K
    Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S134-8. PubMed ID: 12620150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine.
    Timmerman JM; Levy R
    J Immunol; 2000 May; 164(9):4797-803. PubMed ID: 10779787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine.
    Slovin SF; Ragupathi G; Musselli C; Olkiewicz K; Verbel D; Kuduk SD; Schwarz JB; Sames D; Danishefsky S; Livingston PO; Scher HI
    J Clin Oncol; 2003 Dec; 21(23):4292-8. PubMed ID: 14645418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies.
    Livingston P; Zhang S; Adluri S; Yao TJ; Graeber L; Ragupathi G; Helling F; Fleisher M
    Cancer Immunol Immunother; 1997 Jan; 43(6):324-30. PubMed ID: 9067403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Carbohydrate antigens as targets for active specific immunotherapy.
    Ragupathi G
    Cancer Immunol Immunother; 1996 Nov; 43(3):152-7. PubMed ID: 9001568
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Keyhole limpet hemocyanin (KLH) conjugate vaccines as novel therapeutic tools in malignant disorders.
    Schumacher K
    J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R1-2. PubMed ID: 11768617
    [No Abstract]   [Full Text] [Related]  

  • 32. Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells.
    Ragupathi G; Howard L; Cappello S; Koganty RR; Qiu D; Longenecker BM; Reddish MA; Lloyd KO; Livingston PO
    Cancer Immunol Immunother; 1999 Apr; 48(1):1-8. PubMed ID: 10235483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens.
    Wang ZG; Williams LJ; Zhang XF; Zatorski A; Kudryashov V; Ragupathi G; Spassova M; Bornmann W; Slovin SF; Scher HI; Livingston PO; Lloyd KO; Danishefsky SJ
    Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2719-24. PubMed ID: 10716997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Constructing an adenocarcinoma vaccine: immunization of mice with synthetic KH-1 nonasaccharide stimulates anti-KH-1 and anti-Le(y) antibodies.
    Ragupathi G; Deshpande PP; Coltart DM; Kim HM; Williams LJ; Danishefsky SJ; Livingston PO
    Int J Cancer; 2002 May; 99(2):207-12. PubMed ID: 11979435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A cancer vaccine based on fluorine-modified sialyl-Tn induces robust immune responses in a murine model.
    Song C; Zheng XJ; Liu CC; Zhou Y; Ye XS
    Oncotarget; 2017 Jul; 8(29):47330-47343. PubMed ID: 28537884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope).
    Holmberg LA; Oparin DV; Gooley T; Sandmaier BM
    Clin Breast Cancer; 2003 Feb; 3 Suppl 4():S144-51. PubMed ID: 12620152
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A polyvalent vaccine for high-risk prostate patients: "are more antigens better?".
    Slovin SF; Ragupathi G; Fernandez C; Diani M; Jefferson MP; Wilton A; Kelly WK; Morris M; Solit D; Clausen H; Livingston P; Scher HI
    Cancer Immunol Immunother; 2007 Dec; 56(12):1921-30. PubMed ID: 17619878
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of widely consumed botanicals as immunological adjuvants.
    Ragupathi G; Yeung KS; Leung PC; Lee M; Lau CB; Vickers A; Hood C; Deng G; Cheung NK; Cassileth B; Livingston P
    Vaccine; 2008 Sep; 26(37):4860-5. PubMed ID: 18640165
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The case for polyvalent cancer vaccines that induce antibodies.
    Ragupathi G; Livingston P
    Expert Rev Vaccines; 2002 Aug; 1(2):193-206. PubMed ID: 12901558
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases.
    Zhang H; Zhang S; Cheung NK; Ragupathi G; Livingston PO
    Cancer Res; 1998 Jul; 58(13):2844-9. PubMed ID: 9661900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.